Search results for "Delivery"

showing 10 items of 1271 documents

Engineering approaches in siRNA delivery.

2017

siRNAs are very potent drug molecules, able to silence genes involved in pathologies development. siRNAs have virtually an unlimited therapeutic potential, particularly for the treatment of inflammatory diseases. However, their use in clinical practice is limited because of their unfavorable properties to interact and not to degrade in physiological environments. In particular they are large macromolecules, negatively charged, which undergo rapid degradation by plasmatic enzymes, are subject to fast renal clearance/hepatic sequestration, and can hardly cross cellular membranes. These aspects seriously impair siRNAs as therapeutics. As in all the other fields of science, siRNAs management ca…

0301 basic medicine3003siRNAs Delivery vectors in vitro models Mathematical modeling Physical modelingDelivery vectors; In vitro models; Mathematical modeling; Physical modeling; SiRNAs; 3003Pharmaceutical ScienceNanotechnology02 engineering and technologyComputational biologyBiology03 medical and health sciencesDrug Delivery SystemsHumanssiRNAs; Delivery vectors; in vitro models; Mathematical modeling; Physical modelingRNA Small Interferingin vitro modelsPhysical modelingSettore ING-IND/34 - Bioingegneria IndustrialeHydrogelsDelivery vectorsModels Theoretical021001 nanoscience & nanotechnologyDelivery vectorsiRNAsClinical PracticeHydrogel030104 developmental biologyin vitro modelsiRNAMathematical modeling0210 nano-technologyBlood streamDrug Delivery SystemClearanceHumanInternational journal of pharmaceutics
researchProduct

Birth Mode-Related Differences in Gut Microbiota Colonization and Immune System Development.

2018

<b><i>Background:</i></b> The process of early gut colonization is extremely variable among individuals and is influenced by numerous factors. Among these, the mode of birth will strongly shape the early microbial exposure and immune environment of the neonate. <b><i>Summary:</i></b> Here, I review how the concomitant processes of microbiota and immune system development are altered by C-section delivery and the effects of such alterations on long-term health. <b><i>Key messages:</i></b> C-section delivery impinges on microbiota and immune system development through various means: (i) if labor is lacking, intrauterine i…

0301 basic medicineAllergyMedicine (miscellaneous)DiseaseBiologyGut flora03 medical and health sciencesFecesImmune systemTime windowsPregnancymedicineHumansColonizationGut colonizationNutrition and DieteticsCesarean SectionInfant Newbornbiochemical phenomena metabolism and nutritionmedicine.diseasebiology.organism_classificationDelivery ObstetricGastrointestinal Microbiome030104 developmental biologyImmune SystemImmunologyVaginabacteriaFemaleAnnals of nutritionmetabolism
researchProduct

Extracellular Vesicles-Based Drug Delivery Systems: A New Challenge and the Exemplum of Malignant Pleural Mesothelioma

2020

Research for the most selective drug delivery to tumors represents a fascinating key target in science. Alongside the artificial delivery systems identified in the last decades (e.g., liposomes), a family of natural extracellular vesicles (EVs) has gained increasing focus for their potential use in delivering anticancer compounds. EVs are released by all cell types to mediate cell-to-cell communication both at the paracrine and the systemic levels, suggesting a role for them as an ideal nano-delivery system. Malignant pleural mesothelioma (MPM) stands out among currently untreatable tumors, also due to the difficulties in achieving an early diagnosis. Thus, early diagnosis and treatment of …

0301 basic medicineAntineoplastic AgentsReviewexosomesExtracellular vesiclesCatalysisInorganic Chemistrylcsh:Chemistry03 medical and health sciencesdrug delivery systems0302 clinical medicinemedicineHumansexosomedrug delivery systemmalignant pleural mesotheliomaMesotheliomaPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopyDrug Carriersbusiness.industryPleural mesotheliomaMesothelioma MalignantOrganic ChemistryGeneral Medicinemedicine.diseaseMicrovesiclesComputer Science Applications030104 developmental biologylcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisDrug deliveryCancer researchDelivery systemextracellular vesiclebusinessextracellular vesicles
researchProduct

Controlled Transdermal Release of Antioxidant Ferulate by a Porous Sc(III) MOF

2020

Summary The Sc(III) MOF-type MFM-300(Sc) is demonstrated in this study to be stable under physiological conditions (PBS), biocompatible (to human skin cells), and an efficient drug carrier for the long-term controlled release (through human skin) of antioxidant ferulate. MFM-300(Sc) also preserves the antioxidant pharmacological effects of ferulate while enhancing the bio-preservation of dermal skin fibroblasts, during the delivery process. These discoveries pave the way toward the extended use of Sc(III)-based MOFs as drug delivery systems (DDSs).

0301 basic medicineAntioxidantmedicine.medical_treatmentHuman skin02 engineering and technologyArticleInorganic Chemistry03 medical and health sciencesmedicine[CHIM]Chemical Scienceslcsh:ScienceComputingMilieux_MISCELLANEOUSTransdermalMultidisciplinaryintegumentary systemChemistry021001 nanoscience & nanotechnologyBiocompatible materialControlled releaseCombinatorial chemistry3. Good healthChemistry030104 developmental biologyDrug deliveryMedicinelcsh:Q0210 nano-technologyDrug carrierMaterials Structure
researchProduct

Ticket to Ride: Targeting Proteins to Exosomes for Brain Delivery.

2017

Exosomes represent an attractive vehicle for the delivery of biomolecules. However, mechanisms for loading functional molecules into exosomes are relatively unexplored. Here we report the use of the evolutionarily conserved late-domain (L-domain) pathway as a mechanism for loading exogenous proteins into exosomes. We demonstrate that labeling of a target protein, Cre recombinase, with a WW tag leads to recognition by the L-domain-containing protein Ndfip1, resulting in ubiquitination and loading into exosomes. Our results show that Ndfip1 expression acts as a molecular switch for exosomal packaging of WW-Cre that can be suppressed using the exosome inhibitor GW4869. When taken up by floxed …

0301 basic medicineBiocompatibilityRecombinant Fusion ProteinsGene ExpressionComputational biologyBiologyExosomesPermeabilityCell LineExtracellular VesiclesMice03 medical and health sciencesDrug Delivery SystemsDrug DiscoveryGeneticsAnimalsMolecular BiologyPharmacologyIntegrasesbusiness.industryImmunogenicityMembrane ProteinsRNABrainProteinsMicrovesiclesBiotechnologyProtein Transport030104 developmental biologyTargeted drug deliveryBlood-Brain BarrierCommentaryMolecular MedicineOriginal ArticleNasal AbsorptionCarrier ProteinsGenetic EngineeringbusinessMolecular therapy : the journal of the American Society of Gene Therapy
researchProduct

Dextran-based therapeutic nanoparticles for hepatic drug delivery.

2016

Aim: Evaluation of dextran-based nanoparticles (DNP) as a drug delivery system to target myeloid cells of the liver. Materials & methods: DNP were synthesized and optionally PEGylated. Their toxicity and cellular uptake were studied in vitro. Empty and siRNA-carrying DNP were tested in vivo with regard to biodistribution and cellular uptake. Results: In vitro, DNP were taken up by cells of the myeloid lineage without compromising their viability. In vivo, empty and siRNA-carrying DNP distributed to the liver where a single treatment addressed approximately 70% of macrophages and dendritic cells. Serum parameters indicated no in vivo toxicity. Conclusion: DNP are multifunctional liver-s…

0301 basic medicineBiodistributionMaterials scienceCell SurvivalSurface PropertiesBiomedical EngineeringMedicine (miscellaneous)Antigens Differentiation Myelomonocyticchemical and pharmacologic phenomenaBioengineering02 engineering and technologyDevelopmentPharmacologyPolyethylene Glycols03 medical and health scienceschemistry.chemical_compoundMiceIn vivoAntigens CDAnimalsHumansGeneral Materials ScienceTissue DistributionParticle SizeRNA Small InterferingDrug CarriersMice Inbred BALB Corganic chemicalsMacrophageshemic and immune systemsDextransDendritic cell3T3 CellsDendritic Cells021001 nanoscience & nanotechnology030104 developmental biologyDextranRAW 264.7 CellschemistryLiverDrug deliveryToxicityPEGylationNanoparticles0210 nano-technologyDrug carrierNanomedicine (London, England)
researchProduct

Targeting distinct myeloid cell populations in vivo using polymers, liposomes and microbubbles

2016

Identifying intended or accidental cellular targets for drug delivery systems is highly relevant for evaluating therapeutic and toxic effects. However, limited knowledge exists on the distribution of nano- and micrometer-sized carrier systems at the cellular level in different organs. We hypothesized that clinically relevant carrier materials, differing in composition and size, are able to target distinct myeloid cell subsets that control inflammatory processes, such as macrophages, neutrophils, monocytes and dendritic cells. Therefore, we analyzed the biodistribution and in vivo cellular uptake of intravenously injected poly(N-(2-hydroxypropyl) methacrylamide) polymers, PEGylated liposomes…

0301 basic medicineBiodistributionMyeloidPolymersCellBiophysicsMice NudeCapsulesBioengineeringSpleen02 engineering and technologyFlow cytometryBiomaterialsMice03 medical and health sciencesNanocapsulesIn vivoMaterials TestingmedicineAnimalsMyeloid CellsTissue DistributionMolecular Targeted TherapyMicrobubblesmedicine.diagnostic_testbusiness.industryMacrophages021001 nanoscience & nanotechnology3. Good healthCell biologyVisceraNanomedicine030104 developmental biologymedicine.anatomical_structureOrgan SpecificityMechanics of Materials2023 OA procedureLiposomesImmunologyDrug deliveryCeramics and CompositesMicrobubblesTargeted delivery0210 nano-technologybusinessBiomaterials
researchProduct

Skin-derived mesenchymal stem cells as quantum dot vehicles to tumors

2017

Dominyka Dapkute,1,2 Simona Steponkiene,1 Danute Bulotiene,1 Liga Saulite,3 Una Riekstina,3 Ricardas Rotomskis1,4 1Biomedical Physics Laboratory, National Cancer Institute, Vilnius, Lithuania; 2Institute of Biosciences, Vilnius University, Vilnius, Lithuania; 3Faculty of Medicine, University of Latvia, Riga, Latvia; 4Biophotonics Group of Laser Research Center, Faculty of Physics, Vilnius University, Vilnius, Lithuania Purpose: Cell-mediated delivery of nanoparticles is emerging as a new method of cancer diagnostics and treatment. Due to their inherent regenerative properties, adult mesenchymal stem cells (MSCs) are naturally attracted to wounds and sites of inflammation, as well as tumors.…

0301 basic medicineBiophysicsPharmaceutical ScienceConnective tissueBioengineeringBreast Neoplasmsquantum dotsMice SCIDFlow cytometryBiomaterialsCell therapy03 medical and health sciencesIn vivoCell MovementInternational Journal of NanomedicineCell Line TumorDrug DiscoverymedicineAnimalsHumansViability assayParticle SizeCytotoxicityCell ShapeSkinOriginal Researchmesenchymal stem cellsMigration Assaymedicine.diagnostic_testCell DeathChemistryOrganic ChemistryMesenchymal stem cellGeneral MedicineDynamic Light ScatteringEndocytosis030104 developmental biologymedicine.anatomical_structureimmunodeficient miceCancer researchNanoparticlesFemaletumor tropismtumor-specific deliveryInternational Journal of Nanomedicine
researchProduct

Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics

2021

The frequent inefficiency of conventional cancer therapies due to drug resistance, non-targeted drug delivery, chemotherapy-associated toxic side effects turned the focus to bioactive phytochemicals. In this context, curcumin and resveratrol have emerged as potent chemopreventive and chemoprotective compounds modulating apoptotic and autophagic cell death pathways in cancer in vitro and in vivo. As synergistic agents in combination with clinically established anticancer drugs, the enhanced anticancer activity at reduced chemotherapy-associated toxicity towards normal organs can be explained by improved pharmacokinetics, pharmacodynamics, bioavailability and metabolism. With promising precli…

0301 basic medicineCancer ResearchCurcuminPhytochemicalsContext (language use)PharmacologyChemoprevention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsNeoplasmsAnimalsHumansMedicinebusiness.industryChemoprotectionDrug SynergismAntineoplastic Agents Phytogenic030104 developmental biologychemistryResveratrol030220 oncology & carcinogenesisPharmacodynamicsDrug deliveryChemoprotectiveCurcuminNanocarriersbusinessSeminars in Cancer Biology
researchProduct

Dosimetric Impact of Interfractional Variations in Prostate Cancer Radiotherapy—Implications for Imaging Frequency and Treatment Adaptation

2019

Background and purpose: To analyze deviations of the applied from the planned doses on a voxel-by-voxel basis for definitive prostate cancer radiotherapy depending on anatomic variations and imaging frequency. Materials and methods: Daily in-room CT imaging was performed in treatment position for 10 patients with prostate cancer undergoing intensity-modulated radiotherapy (340 fraction CTs). Applied fraction doses were recalculated on daily images, and voxel-wise dose accumulation was performed using a deformable registration algorithm. For weekly imaging, weekly position correction vectors were derived and used to rigidly register daily scans of that week to the planning CT scan prior to d…

0301 basic medicineCancer Researchmedicine.medical_treatmentRectumlcsh:RC254-28203 medical and health sciencesProstate cancerorgans-at-risk0302 clinical medicineProstateDosimetryMedicineOriginal ResearchDose accumulationdosimetrybusiness.industryimage-guided radiotherapymedicine.diseaseprostate cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstumor control probabilityRadiation therapyConformity index030104 developmental biologymedicine.anatomical_structureOncologyTreatment delivery030220 oncology & carcinogenesisbusinessNuclear medicineFrontiers in Oncology
researchProduct